Indica Labs

The cleared product is a platform, not an algorithm. HALO AP Dx is an enterprise digital pathology workspace whose FDA clearance covers primary diagnosis, meaning viewing and diagnosing from digital slides, and that clearance rests on the platform plus scanner pairing rather than on AI performance. AI is a genuine and central part of the offering, including hosted third party algorithms and the company's own image analysis, but a laboratory could deploy the cleared platform for digital primary diagnosis and use no AI at all. Graded C on the same principle applied to ModMed and Elation Health: an established platform that adds AI is not the same as a product that is AI.

The platform's cleared function is to let a pathologist make the primary diagnosis on a digital slide, so the human is the diagnostic actor by design. Algorithms accessed through the associated store are assistive and, as the company notes, carry their own separate regulatory classifications, which is an important disclosure: platform clearance does not extend to the algorithms running on it. A buyer must evaluate the platform and each algorithm independently.

The regulatory scope is stated with real precision, including clearance numbers tied to named scanner hardware, and the company is consistently explicit about which product is cleared and which is research use only. What is not published is model level detail on its own AI, training data, or validation, because the disclosure emphasis sits on platform clearance and integration rather than algorithm performance. Transparent about scope, quiet about models.

The 510(k) clearances for primary diagnosis carry validation behind them, and the platform reports deployment at hospitals, contract research organizations, clinical laboratories, and government and academic institutions. But no peer reviewed outcome or concordance literature specific to the platform was located in this review, and the company's public evidence is framed around regulatory milestones and feature releases rather than clinical study results. Cleared and widely deployed, lightly published.

Better documented than most pathology vendors here, though framed as regulatory compliance rather than AI safety specifically. The company states built in compliance with FDA 21 CFR Part 11, which governs electronic records and audit trails, alongside HIPAA and, for the research product, GDPR. Part 11 compliance is meaningful for a diagnostic system of record because it implies audit trail and record integrity controls. What is absent is AI specific safety documentation such as failure mode disclosure or monitoring of hosted algorithms.

HIPAA compliance is stated explicitly and repeatedly as a built in property of both HALO AP Dx and HALO AP, which is more than most vendors in this category publish. A specific BAA commitment or trust documentation was not located, so the posture is asserted compliance rather than a published contractual position, but it is stated plainly by a US headquartered vendor selling into US clinical laboratories.

ISO 13485:2016 certification is stated, which covers medical device quality management rather than information security, and 21 CFR Part 11 compliance addresses electronic record controls. Neither substitutes for SOC 2 or ISO 27001, and no such attestation or trust center was located. More documented than an unrated vendor, short of a security certification.

Cleared for primary diagnosis, which is the highest bar in digital pathology, and cleared twice: K232833 with the Hamamatsu NanoZoomer S360MD in 2024, then K252762 in December 2025 adding the Leica Biosystems Aperio GT 450 DX scanner. CE-IVDR marked in Europe, the UK, and Switzerland. The critical nuance, which the company states plainly and repeatedly, is that clearance is scanner specific: HALO AP Dx is cleared only with named scanners, and the separate HALO AP product is research use only in the US and explicitly not cleared for diagnostic use. Credit for regulatory achievement and for unusually disciplined disclosure of exactly what is and is not cleared.

No formal governance framework, bias disclosure, or subgroup analysis was located. The platform hosts third party algorithms with their own regulatory classifications, which raises a governance question about who monitors algorithm performance in production, and the vendor does not publish an answer.

Interoperability is the core of the value proposition rather than a feature. The platform is described as an integration engine bringing together diverse software and hardware, it is cleared across scanners from two different manufacturers, and it hosts third party algorithms through an associated store, making it a hub other vendors plug into. The Leica clearance specifically covers a DICOM compatible scanner, which matters because DICOM is the standard that makes pathology images portable across systems. Multi vendor hardware clearance plus third party algorithm hosting is the strongest interoperability position available in this category.

Specific hosting, tenancy, and data residency terms were not located in the materials reviewed. As an enterprise platform handling whole slide images, deployment architecture is likely configurable per customer, but the vendor does not publish the options.

No pricing is published for the platform or for algorithms accessed through the store. A buyer should note that total cost includes cleared scanner hardware, the platform, and separately licensed algorithms, and that the scanner specific nature of the clearance means hardware choice and software cost are coupled decisions rather than independent ones.

Broad by construction. Clearance covers primary diagnosis of surgical pathology slides from formalin fixed paraffin embedded tissue generally, not a specific tumor type, so scope spans anatomic pathology rather than one indication. The company also serves life science discovery, translational research, clinical trials, and companion diagnostic development alongside clinical workflows. That span across research and clinical settings, plus tumor board and second opinion workflows, is wider than any single algorithm vendor can offer.